Nincs elég ideje elolvasni a teljes cikket? Hallgassa meg az összefoglalót 2 percben.

For years, the Medical Device Regulation (MDR) was viewed as a demanding but manageable evolution of the MDD. The industry expected a linear transition: update the files, submit the evidence, and move on.

The reality has been a systemic shock. Several years into the application, the transition remains dangerously incomplete. We aren’t just seeing a regulatory backlog; we are witnessing a structural redesign of how MedTech companies manage evidence, portfolios, and market access.

Why the “Linear Transition” Failed

The original industry assumption was that documentation efforts would be incremental. That assumption crashed against two harsh realities:

1. Systemic Capacity Crashing: The number of designated Notified Bodies plummeted while the workload per certificate tripled.

2. The “Ground-Up” Rebuild: For legacy devices, “updating” files wasn’t an option. MDR demands a level of clinical evaluation and post-market surveillance (PMS) that requires rebuilding technical files from scratch.

The Strategic Pivot: MDR is no longer a “Quality project.” It is a business-viability test that determines which products survive and which are quietly withdrawn.

3 Internal Friction Points Stalling MDR Programs

While industry talk focuses on external bottlenecks (Notified Bodies), the most lethal delays often happen inside the plant.

1. The Regulatory “Bandwidth” Crisis

Regulatory Affairs (RA) teams are no longer just filing paperwork; they are performing forensic documentation rebuilds. When a portfolio of hundreds of devices hits this wall simultaneously, the workload exceeds internal capacity by orders of magnitude.

2. The Portfolio Rationalization Trap

MDR forces uncomfortable board-level questions:

• Does the margin on this niche device justify the €50k+ recertification cost?
• Should we redesign the product now or exit the market?
• Az eredmény: Delayed decisions on product exits lead to “zombie projects” that suck resources away from critical, high-revenue lines.

3. The Cross-Functional Drift

MDR touches every department, but they often move at different speeds:

• RA manages the submission timeline.
• Mérnöki tevékenység implements labeling and UDI changes.
• Gyártás adjusts production to meet new validation standards.
• The Risk: Without a central “mission owner,” these functions drift, causing certification dates to slip and market access to vanish.

The Market Consequences: A Reshaped Landscape

The impact of these bottlenecks is now visible in the European healthcare ecosystem:

• Reduced Diversity: Niche and “orphan” devices are disappearing as compliance costs outpace commercial value.
• Procurement Risk: Hospital supply chains are becoming more fragile as smaller manufacturers exit the market.
• Barrier to Entry: The “regulatory moat” is now so wide that only the most well-capitalized firms can navigate it.

How Leading Manufacturers Are Stabilizing

The companies progressing through MDR aren’t necessarily the ones with the most money—they are the ones treating it as an Operational Transformation.

The Role of Senior Intervention

At the peak of a transition, internal teams are often “running the business” while “changing the business.” This is a recipe for burnout. Many successful sites are now using interim regulatory leadership, not for advice, but for temporary senior ownership.

They act as the “connective tissue” between compliance logic and manufacturing reality.

Summary: From Documentation to Redesign

The MDR transition has proved that regulatory compliance is no longer a background function. It is now the core driver of MedTech strategy.

The final takeaway is clear:

MDR success is not found in the technical files alone. It is found in the ability to convert regulatory requirements into a workable operational model. Companies that fail to make this conversion won’t just lose their certificates, they will lose their market position.